Cargando…

Preclinical Evaluation of Vemurafenib as Therapy for BRAF(V600E) Mutated Sarcomas

The BRAF(V600E) mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines. Methods: Four sarcoma cell lines harboring the BRAF(V600E) mutation, representing liposarcomas (SA-4 and SW872), Ewing sarcoma (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gouravan, Sarina, Meza-Zepeda, Leonardo A., Myklebost, Ola, Stratford, Eva W., Munthe, Else
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979358/ https://www.ncbi.nlm.nih.gov/pubmed/29570692 http://dx.doi.org/10.3390/ijms19040969

Ejemplares similares

Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
por: Hanes, Robert, et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Characterization of Liposarcoma Cell Lines for Preclinical and Biological Studies
por: Stratford, Eva W., et al.
Publicado: (2012)

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
por: Fisher, Rosalie, et al.
Publicado: (2012)

Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
por: Serguienko, Anastassia, et al.
Publicado: (2014)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF(V600E) Mutated Parent- and Vemurafenib-Resistant Melanoma
por: Fu, Yige, et al.
Publicado: (2019)

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf(V600E) Melanoma
por: Signetti, Laurie, et al.
Publicado: (2020)

Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH
por: Evseev, Dmitry, et al.
Publicado: (2023)

BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
por: Rustad, E H, et al.
Publicado: (2015)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAF(V600E) Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia
por: Furfaro, Anna Lisa, et al.
Publicado: (2022)

Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing BRAF(V600E) -Mutated Erdheim–Chester Disease: A Case Report
por: Razanamahery, Jérôme, et al.
Publicado: (2022)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
por: Wang, Xiaomeng, et al.
Publicado: (2023)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
por: Moiseyenko, Fedor V., et al.
Publicado: (2019)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023)

Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib
por: Lopez-Rios, Fernando, et al.
Publicado: (2013)

The clinical response to vemurafenib in a patient with a rare BRAF(V600DK601del) mutation-positive melanoma
por: Trudel, Stéphanie, et al.
Publicado: (2014)

Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation
por: Sahadudheen, K., et al.
Publicado: (2016)

Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF(V600E)-Specific Inhibitor)
por: Torres-Collado, Antoni Xavier, et al.
Publicado: (2018)

Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report
por: Dooley, Andrew J., et al.
Publicado: (2016)

Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAF(V600E)-Mutant CRC: A Case Report and Review
por: Cho, Su Min, et al.
Publicado: (2021)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines
por: Wessel Stratford, Eva, et al.
Publicado: (2014)

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation–positive melanoma
por: Dréno, Brigitte, et al.
Publicado: (2018)

Vemurafenib in patients with BRAF(V600) mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
por: Chapman, P B, et al.
Publicado: (2017)

Vemurafenib in Chinese patients with BRAF(V600) mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
por: Si, Lu, et al.
Publicado: (2018)

Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b
por: Engkvist, M. E., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jjd03oou9vpbatfhu72r5nc5cv